resminostat
Small moleculeexperimental
Resminostat is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents. — Wikipedia
Clinical trial activity
7 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
1
Earliest trial started Jul 1, 2009 (NCT00943449)
Timeline
Indications
Approved for
Mechanism of action
- Histone deacetylaseINHIBITOR
Histone deacetylase inhibitor
- Histone deacetylase 1 (HDAC1) ↗
- Histone deacetylase 3 (HDAC3) ↗
- Histone deacetylase 6 (HDAC6) ↗
- Histone deacetylase 2 (HDAC2) ↗
- Histone deacetylase 5 (HDAC5) ↗
- Histone deacetylase 7 (HDAC7) ↗
- Histone deacetylase 8 (HDAC8) ↗
- Histone deacetylase 11 (HDAC11) ↗
- Histone deacetylase 4 (HDAC4) ↗
- Histone deacetylase 9 (HDAC9) ↗
- Histone deacetylase 10 (HDAC10) ↗
- Histone deacetylase 8
- Histone deacetylase 10
- Histone deacetylase 2
- Histone deacetylase 3
- Histone deacetylase 4
- Histone deacetylase 6
- Histone deacetylase 9
- Histone deacetylase 11
- Histone deacetylase 5
- Histone deacetylase 7
- Histone deacetylase 1
- Histone deacetylase (HDAC1 and HDAC2)
- Histone deacetylase 1/3/5/8
- Histone deacetylase 1/2/3/6
- Histone deacetylase 1/2/3
- Histone deacetylase 1/8
- Histone deacetylase 1/6
- Class 1 histone deacetylase
- Histone deacetylase 6/3
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)Cc1ccc(S(=O)(=O)n2ccc(/C=C/C(=O)NO)c2)cc1- Mol. weight
- 349.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaResminostat ↗
- ChEMBLCHEMBL4296717 ↗
Also known as
- 4sc-201
- 4sc-201
- ras2410
- ras 2410
- ras-2410
- resminostat
- resminostat
- resminostat
- resminostat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04955340 | Phase 1 | Sep 27, 2021 | 4SC AG |
| NCT04525729 | Phase 4 | Jul 1, 2020 | Jiao Tong University, Ningbo Yinzhou People's Hospital, Ningxia Medical University, Shanghai Ruijin Hospital North, Sun Yat-Sen University, Tongji University, Xiamen Hongai Hospital, Zhejiang University |
| NCT02953301 | Phase 2 | Nov 1, 2016 | 4SC AG, Johannes Wesling Klinikum, Minden, Germany |
| NCT02400788 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | Yakult Honsha Co., LTD |
| NCT01277406 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | 4SC AG, University of Heidelberg |
| NCT01037478 | Phase 2 | Dec 1, 2009 | 4SC AG |
| NCT00943449 | Phase 2 | Jul 1, 2009 | 4SC AG |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 4SC AG | For profit | 5 | 5 | 2 | 2009 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Johannes Wesling Klinikum, Minden, Germany | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Ningbo Yinzhou People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Ningxia Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Shanghai Ruijin Hospital North | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Tongji University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Heidelberg | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Xiamen Hongai Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Yakult Honsha Co., LTD | For profit | 1 | 1 | 1 | 2013 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2020 |
12 organizations
Page 1 / 1